Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 31Expanded_access 2Observational 1

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Multiple Myeloma 1Melanoma 1Liver Neoplasms 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Melphalan × Clear all
NCT00799539 2015-12-02

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Janssen-Ortho Inc., Canada

No longer available
Plasma cell

Multiple Myeloma

NCT01728051 2013-10-23

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

Delcath Systems Inc.

No longer available
DermatologicGastrointestinal

Uveal Melanoma, Liver Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡